- Home
- MCI vs DCTH Comparison
MCI vs DCTH Comparison
Compare MCI & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCI
- DCTH
- Stock Information
- Founded
- MCI 1971
- DCTH 1988
- Country
- MCI United States
- DCTH United States
- Employees
- MCI N/A
- DCTH N/A
- Industry
- MCI Trusts Except Educational Religious and Charitable
- DCTH Medical/Dental Instruments
- Sector
- MCI Finance
- DCTH Health Care
- Exchange
- MCI Nasdaq
- DCTH Nasdaq
- Market Cap
- MCI 419.4M
- DCTH 388.3M
- IPO Year
- MCI N/A
- DCTH N/A
- Fundamental
- Price
- MCI $22.87
- DCTH $11.20
- Analyst Decision
- MCI
- DCTH Strong Buy
- Analyst Count
- MCI 0
- DCTH 4
- Target Price
- MCI N/A
- DCTH $24.50
- AVG Volume (30 Days)
- MCI 40.4K
- DCTH 493.0K
- Earning Date
- MCI 01-01-0001
- DCTH 11-07-2025
- Dividend Yield
- MCI 8.46%
- DCTH N/A
- EPS Growth
- MCI N/A
- DCTH N/A
- EPS
- MCI 1.82
- DCTH 0.06
- Revenue
- MCI N/A
- DCTH $70,240,000.00
- Revenue This Year
- MCI N/A
- DCTH $159.22
- Revenue Next Year
- MCI N/A
- DCTH $42.78
- P/E Ratio
- MCI $9.88
- DCTH $201.97
- Revenue Growth
- MCI N/A
- DCTH 491.35
- 52 Week Low
- MCI $12.96
- DCTH $8.08
- 52 Week High
- MCI $19.24
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- MCI 74.55
- DCTH 51.88
- Support Level
- MCI $21.02
- DCTH $10.61
- Resistance Level
- MCI $21.90
- DCTH $11.38
- Average True Range (ATR)
- MCI 0.53
- DCTH 0.46
- MACD
- MCI 0.15
- DCTH 0.02
- Stochastic Oscillator
- MCI 93.64
- DCTH 45.11
About MCI Barings Corporate Investors
Barings Corporate Investors is a closed-end management investment company. Its investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. The Trust's principal investments are privately placed, below-investment grade, long-term debt obligations, including bank loans and mezzanine debt instruments. The Trust typically purchases these investments, which are not publicly tradable, directly from their issuers in private placement transactions, and the investments are typically made to small or middle market companies.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.